An interventional study of Pegvisomant and Somatostatin analog (lanreotide or octreotide) in Acromegaly, Insulin Resistance and Impaired Glucose Tolerance, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-26.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy.
Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.
196 studies on the registry are indexed under Acromegaly; 18 are open to participants now.
This study's enrollment of 18 is below the median of 43 across 115 interventional studies indexed under Acromegaly.
Browse Acromegaly studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
Drug: Pegvisomant · Drug: Somatostatin analog (lanreotide or octreotide)
Somatostatin analog, unaltered dosage
Drug: Somatostatin analog (lanreotide or octreotide)
Pegvisomant s.c 15-30 mg 2 times a week
Also known as: Somavert
Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
Insulin sensitivity
Time frame: 0 and after 24 weeks
Glucose tolerance
Time frame: 0 and after 24 weeks
Symptoms, QoL questionaire
Time frame: 0, 12 and 24 weeks
Intrahepatic and intramyocellular fat
Time frame: 0 and 24 weeks
Substrate metabolism
Time frame: 0 and 24 weeks
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus